Phase 2Completed
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study
- Sponsor
- Novo Nordisk A/S (Industry)
- Enrolment
- 448 enrolled
- Conditions
- Type 2 Diabetes (T2D)
- Interventions
- NNC0487-0111 subcutanous; Placebo (NNC0487-0111 subcutanous); NNC0487-0111 oral; Placebo (NNC0487-0111 oral)
- Ages
- adults, older adults
- Registry
- NCT06542874
From the registry
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Primary outcomes
- Change in HbA1c